As Chief Medical Officer, Laszlo has the overall responsibility for clinical development activities. He is a seasoned early and late-stage clinical R&D expert having held numerous global clinical leadership positions at Ferring (2008/2012), Novartis (2012-2017), NIBR (2017-2020), and Bayer headquarters (2020-2024). His diverse clinical expertise includes women’s health, obesity/metabolic syndrome, osteoporosis, osteoarthritis, sarcopenia and other muscle wasting conditions, thrombosis and cardiovascular diseases.
Laszlo obtained his MD degree in Hungary, his PhD (Cardiovascular Pharmacology), Doctor of Medical Sciences degree (Obesity/Cardiometabolic research), and executive MBA in Denmark.
